A stem-cell myeloproliferative disorder involving T-and B-cell, and myeloid lineages, is associated with three dierent translocations with a breakpoint in region p11-12 of chromosome 8: t(6;8)(q27;p11), t(8;9)(p11;q33), and t(8;13)(p12;q12), respectively. Using¯uorescence in situ hybridization (FISH), we have analysed blood cells from a series of ®ve patients carrying these dierent translocations. We have identi®ed cosmids from chromosome region 8p11-12 that span the breakpoint in all the cases. They are speci®c for the FGFR1 gene that encodes a receptor for members of the FGF family. The breakpoint was further detected by Southern and pulsed-®eld gel electrophoresis analyses with probes from the FGFR1 locus.
Keywords: FGFR1 gene; leukemia; lymphoma; human chromosome pairs 6, 8, 9, 13; translocation; fluorescence in situ hybridization; stem cell; hematopoiesis Cloning the breakpoint of recurrent chromosome translocations with myeloid disorders has identi®ed genes important for normal myeloid development and in the generation of various myeloid neoplasia, including acute and chronic myelogenous leukemias, myelodysplastic syndromes and myeloproliferative disorders (MPD) (Sawyers et al., 1991; Rabbitts, 1994; Drexler et al., 1995; Zeleznik-Le et al., 1995; Mitelman et al., 1997) . The short arm of chromosome 8, region p11-12, is involved in reciprocal translocations in acute myeloid leukemia (AML), subtype M5, and myelomonocytic leukemias with t(8;14) (p11;q11.1) (Slovak et al., 1991) , t(8;22)(p11;q13) (LaõÈ et al., 1992) , and t(8;16)(p11;p13) (Bernstein et al., 1987; Heim et al., 1987; LaõÈ et al., 1987; Mitelman and Heim, 1992; Stark et al., 1995; Rodrigues Pereira Velloso et al., 1996; Sainati et al., 1996) , respectively. In the latter, the 8p11 gene involved, MOZ (monocytic leukemia zinc ®nger protein), has been identi®ed recently (Borrow et al., 1996) . Another myeloproliferative disorder associated with abnormal proliferation of several blood lineages and chromosomal translocations in 8p11-12 has been identi®ed (see MacDonald et al., 1995, for review) . This clinicopathologic entity, ®rst described associated with t(8;13)(p11;q11) (Fagan et al., 1993; Leslie et al., 1994; MacDonald et al., 1994; Aguiar et al., 1995; Behringer et al., 1995; Inhorn et al., 1995; Kempsi et al., 1995; Naeem et al., 1995; Michaux et al., 1996) , comprises cases with other translocation partners: at 6q27 (Vannier et al., 1984; Elsner et al., 1994) , and 9q32-34 (Friedho et al., 1983; Lewis et al., 1983; Oscier et al., 1985; Jotterand-Bellomo et al., 1992; Nakayama et al., 1996; van den Berg et al., 1996) . These chromosomal alterations are relatively unfrequent, and the genes targeted by the translocations have not been identi®ed yet. We are studying the 8p11-21 alterations found in hemopathies, by using yeast arti®cial chromosomes (YAC) from a contig covering the corresponding region (Dib et al., 1995) . We have previously identi®ed a YAC that spans the t(8;22) breakpoint (Soenen et al., 1996) .
In the present work, our aim was to identify the localization of the 8p11-12 breakpoints in MPD, and to determine whether or not the same 8p locus is involved in all the chromosome translocations, in support of the hypothesis that its alteration may be a crucial tumorigenic step in the genesis of these malignancies . Five patients with clinical diagnosis of MPD were selected and studied. The 8p11-12 chromosomal region was associated with 6q27 in two cases, with 9q33 in one case, and with 13q12 in two cases. Details of cases are presented in Table 1 . In parallel, a six-week old severe combined immunode®cient (SCID) female mouse was inoculated intraperitoneally with pleural¯uid cells from patient 4. After engraftment (2 months), malignant human cells were collected from abdominal nodes and injected repeatedly into female SCID mice (Jacrot et al., manuscript in preparation). At passage number 13, the karyotype and the immunophenotypic analysis (data not shown) of the human neoplastic cells were checked and found to be identical to that of the pleural¯uid fresh malignant cells with the exception that only the clone with three derivative 13 is present (Table 1) . Passage 13 cells were hereafter named SCID t(8;13) cells, and used in subsequent experiments.
For the de®nition of the 8p11-12 breakpoint, YACs 770C2 and 959A4 (Dib et al., 1995) were mapped on tumor metaphase chromosomes from patient 4 with a translocation t(8;13)(p12;q12). YAC 959A4 spanned the breakpoint (data not shown). Subsequent FISH studies were done using SCID t(8;13) cells. FISH analysis with YAC 959A4 showed hybridization signals on the normal 8, the two der(8) and the three der(13) (data not shown). This analysis showed that the cells recovered from the t(8;13) SCID mouse were a good experimental system. Michaux et al. (1996) . SCID t(8;13) cells derive from PF of patient 4 a b Figure 1 Detection of the t(6;8), t(8;9) and t(8;13) breakpoint on chromosome region 8p11-12 by FGFR1 cosmids. (a) The EcoRI map of the FGFR1 locus is shown. Vertical bars represent EcoRI sites. Below are the overlapping cosmid inserts either isolated from a genomic library from YAC 959A4 (cos IA7), or obtained from previous work (cos 134.6; cos 134.8) (Lafage et al., 1992) . The name of the corresponding cosmid clone is indicated on the left. (b) Fluorescence in situ hybridization (FISH) mapping of cosmid 134.8 labeled with digoxigenin (in red) on chromosomes from patients with myeloproliferative disorder who had a t(6;8)(q27;p11) (left panel) or a t(8;9)(p11;q33) (middle panel). In the right panel, FISH analysis was done on metaphase spreads from cells from patient 4 (see Table 1 ) whose karyotype shows two translocations t(8;13)(p12;q12) associated with a supernumerary der(13), and recovered from a SCID mouse engraftment. A cosmid, the insert of which maps telomeric to the FGFR1 locus, was labeled with biotin (in green) and used as marker for the der(6), der(9), and der(13) chromosomes. In the middle and right panels, a third cosmid (also labeled with biotin (green)), and localized on 8qter, was hybridized in addition to the two others. It can be seen on the normal 8, and all the der(8) chromosomes. Arrows point to the der(6), der(9), and der(13) chromosomes; arrowheads show the der(8) chromosomes At the time of the experiments, the ®broblast growth factor receptor 1 (FGFR1) gene, which maps to 8p12 (Ruta et al., 1988; Lafage et al., 1992) , was the only known gene present on YAC 959A4. A 2.5 kb FGFR1 cDNA containing the complete coding sequence was obtained from M Jaye (RhoÃ ne-Poulenc-Rorer). Probes previously generated from this cDNA (Lafage et al., 1992) were used to screen a genomic library we constructed from YAC 959A4. A cosmid contig was assembled by comparative restriction mapping with the positive clones, and with cosmids obtained from a previous study (Lafage et al., 1992) . Three cosmids were selected for further analysis: cosmids 134.6 and 134.8 (Lafage et al., 1992) , and cosmid IA7 from YAC 959A4 (Figure 1a) . The cosmid DNAs were digoxigenin-labeled and detected with antibodies conjugated with TRITC, according to procedures previously described . FISH mapping of the cosmid clones on metaphase spreads from SCID t(8;13) cells revealed that cosmid 134.6 mapped on the der(8) chromosomes, whereas both cosmids IA7 and 134.8 spanned the breakpoint. Results for cosmid 134.8 are shown in Figure 1b , 1991) . 5'UTR, and 3'UTR correspond to the 5' and 3' untranslated sequences, respectively. The position of the probes used in this study are indicated. BB1 and OL9 probes correspond to 1.15 kb BglII ± BglII and 0.5 kb BglII ± EcoRI fragments of FGFR1 cDNA, respectively. Restriction enzyme sites are: EcoRI (E); BglII (Bg). (c) Left and middle panels: Southern blot analyses of high-molecular-weight-DNA from cells from patient 4 carrying the t(8;13)(p12;q12) translocation, and recovered from SCID mouse. Genomic DNA samples (10 mg) from SCID t(8;13) cells (SCID), and from the K1341 8317 human lymphoblastoid cell line (8317), were digested with BamHI, HindIII, and XbaI. The same blot was sequentially hybridized with the BBI (left panel) and OL9 (middle panel) probes, respectively. The BBI probe recognized two rearranged fragments of 13 and 20 kb (arrows) in BamHI-digested SCID DNA, and the OL9 probe detected a 12 kb rearranged HindIII fragment (arrow). The same 12 kb rearranged fragment was detected in HindIII-digested DNA from fresh bone marrow malignant cells recovered from the patient (t(8;13)). Right panel: High-molecularweight-BssHII-digested DNA from SCID, and lymphoblastoid (8317) 
FGFR1 gene spans the breakpoint in 8p11-12 MPD M Chaffanet et al chromosome 8, the two der(8), and the three der(13). These data are consistent with a pter-3'FGFR1-5'FGFR1-cen orientation of the FGFR1 gene on chromsome 8 (Figure 1a) . The same results were obtained using fresh malignant cells from patient 4, from whom the SCID t(8;13) cells derived, but from patient 5 as well (data not shown). FISH experiments were done on cells from patients 1 and 2, both carrying a translocation t(6;8)(q27;p11), and from patient 3 with a t(8;9)(p11;q33). Both cosmids 134.8 and IA7 spanned the breakpoints. Results for cosmid 134.8 are shown in Figure 1b with hybridization signals on the normal 8, the der(8) and either the der(6) ( Figure 1b, left panel) , or the der(9) (Figure 1, middle panel) chromosomes. These results demonstrate that the MPD studied here have close or identical 8p11-12 breakpoints, independently of the chromosome partners.
The structure and organization of the FGFR1 encoded product and cDNA, as well as the genomic map of the FGFR1 locus are shown in Figure 2 (a, b, and e, respectively). The breakpoint was detected by Southern blot analysis (Figure 2c ) using single copy FGFR1 probes (BB1, OL9; Figure 2b ) and restriction enzyme-digested DNA from SCID t(8;13) cells and fresh bone marrow malignant cells from patient 4. BB1 detected two rearranged fragments (13 and 20 kb) in BamHI-digested DNA tumor samples (Figure 2c , left panel) and OL9 detected a 12 kb rearranged HindIIII fragment (Figure 2c , middle panel), as compared with the restriction pattern of the lymphoblastoid cell line K1341 8317 (Centre du Polymorphisme Humain, Paris) used as control. Both BB1 and OL9 probes revealed a 15 kb XbaI fragment in DNA tumor samples, and a 12 kb fragment in the control cell line. The strong hybridization of the rearranged fragments in SCID t(8;13) cells correlates with the presence of three derivative der(13) chromosomes (see Table 1 ). In addition, the XE1 probe, isolated from the 3' end of the FGFR1 locus (Figure 2e ), detected an additional 170 kb BssHII fragment in pulsed-®eld gel electrophoresis analysis (Figure 2c, right panel) . Additional experiments were done using DNA derived from lymphocytes from ten normal donors or from patients with other tumor types. No rearrangements were detected in all the cases examined, excluding a frequent polymorphism at the human FGFR1 locus (data not shown). Fragments of 30 kb and 15 kb, respectively in BamHI-and HindIII-digested NIH3T3 murine DNA, were detected using OL9 probe and lowstringency Southern blot hybridization, but not in SCID t(8;13) DNA (data not shown).
The expression of the FGFR1 gene was investigated by Northern blot analysis using the OL9 probe. As previously shown (Theillet et al., 1993) , FGFR1 is expressed as a 4.4 kb transcript. In this study, the wildtype 4.4 kb transcript is seen in the control lymphoblastoid cell line Jurkat, and a novel 5 kb transcript (likely to correspond to the derivative chromosome 13) was detected in SCID t(8;13) cells RNA (Figure 2d ). The potential reciprocal translocation transcript was not detected.
We thus identi®ed two cosmids speci®c for the FGFR1 gene that spanned the breakpoint in ®ve patients with MPD associated with three dierent translocations involving 8p11-12: t(6;8)(q27;p11), t(8;9)(p11;q33), and t(8;13)(p12;q12), respectively. This 8p11-12 myeloproliferative disorder is phenotypically distinct from acute monoblastic and myelomonocytic leukemia with t(8;16)(p11;p13) (Bernstein et al., 1987; Heim et al., 1987; LaõÈ et al., 1987; Mitelman and Heim, 1992; Stark et al., 1995; Rodrigues Pereira Velloso et al., 1996; Sainati et al., 1996) , and with t(8;22)(p11;q13) (LaõÈ et al., 1992) , respectively. In addition, the breakpoints of t(8;16) and t(8;22) are dierent from each other, and are both localized centromeric to the breakpoint involved in MPD. We recently identi®ed a YAC (782H11) spanning the translocation breakpoint t(8;22) centromeric to the 959A4 YAC clone (Soenen et al., 1996) . MOZ, identi®ed by positional cloning at the chromosome 8 breakpoint of the t(8;16) translocation (Borrow et al., 1996) maps near the PLAT gene (AdeÂ laõÈ de et al., 1997, submitted) .
The same localization of the 8p11-12 breakpoint in the three dierent translocations associated with myeloproliferative disorder strengthened the hypothesis of a single nosological entity, as stated by MacDonald et al. (1995) . This new clinicopathologic entity is characterized by T-or B-cell lymphoblastic lymphoma, eosinophilia, myeloid hyperplasia, and evolution towards acute myelogenous leukemia and seems to be associated with a multilineage precursor (Fagan et al., 1993; Naeem et al., 1995; Leroux et al., 1997, submitted) . Our data suggest that the gene important in the development of 8p11-12 myeloproliferative syndrome is the same in all the three types of translocation. The FGFR1 gene, encoding a tyrosine kinase receptor for members of the ®broblast growth factor family (Johnson and Williams, 1993) , is a potential oncogene (Theillet et al., 1993; Dib et al., 1995) , and is likely to be involved in these translocation events.
